Update sul danno macrovascolare: fisiopatologia e indicazioni per la prevenzione
|
|
- Donald Adams
- 5 years ago
- Views:
Transcription
1 Update sul danno macrovascolare: fisiopatologia e indicazioni per la prevenzione Marco Giorgio Baroni Department of Experimental Medicine Sapienza University of Rome, Italy
2 Il sottoscritto Marco Giorgio Baroni dichiara di aver ricevuto negli ultimi due anni compensi o finanziamenti dalle seguenti Aziende Farmaceutiche e/o Diagnostiche: - Sanofi - Novo Nordisk - Abbott - Takeda Dichiara altresì il proprio impegno ad astenersi, nell ambito dell evento, dal nominare, in qualsivoglia modo o forma, aziende farmaceutiche e/o denominazione commerciale e di non fare pubblicità di qualsiasi tipo relativamente a specifici prodotti di interesse sanitario (farmaci, strumenti, dispositivi medico-chirurgici, ecc.).
3 The Emerging Risk Factors Collaboration JAMA. 2015;314: Association of Cardiometabolic Multimorbidity With Mortality 2x 2x 2x 2x
4 Diabetes and Survival, According to Sex and Diabetes Status. 7 Men Non-vascular deaths 7 Women 6 Vascular deaths 6 Years of life lost Age (year) Age (year) On average, a 50-year old with diabetes but no history of vascular disease is ~6 years younger at time of death than a counterpart without diabetes The Emerging Risk Factors Collaboration. N Engl J Med 2011;364:
5 Hazard Ratios for Major Causes of Death, according to Baseline Levels of Fasting Glucose The Emerging Risk Factors Collaboration. N Engl J Med 2011;364:
6 Iperglicemia come moltiplicatore.. Svensson et al. Diab Vasc Dis Res 2013;10: Das et al. Am Heart J 2006;151:
7 All Cause Mortality Intensive vs Standard Glucose Lowering CI: confidence interval; HR: hazard ratio. Ray KK et al Lancet 2009;373:
8 Major cardiovascular Events Intensive vs Standard Glucose Lowering Turnbull FM et al Diabetologia 2009; 52:
9 *CV mortality, non-fatal MI, non-fatal stroke Effect of Glucose-Lowering Drugs on 3-Point MACE* Study Year Glucose-lowering drug in T2DM Patients HR 95% CI P-value PROACTIVE 2005 Pioglitazone ORIGIN 2012 Insulin glargine NS DEVOTE 2017 Insulin degludec NS SAVOR 2013 Saxagliptin NS EXAMINE 2013 Alogliptin NS TECOS 2015 Sitagliptin NS ELIXA 2015 Lixisenatide NS EMPA-REG 2015 Empagliflozin LEADER 2016 Liraglutide Favors study drug Favors placebo 0.01 SUSTAIN Semaglutide CANVAS 2017 Canagliflozin ,2
10 Turner RC et al BMJ 1999;316: UKPS 23: Risk Factors for CHD HbA1c (%) Age (yrs) Estimated HR Systolic BP (mmhg) LDL-cholesterol mmol/l) Estimated HR Estimated HR Estimated HR
11 Effect of Glucose-Lowering Drugs on 3-Point MACE* Study Year Glucose-lowering drug in T2DM Patients HR 95% CI P-value PROACTIVE 2005 Pioglitazone ORIGIN 2012 Insulin glargine NS DEVOTE 2017 Insulin degludec NS SAVOR 2013 Saxagliptin NS EXAMINE 2013 Alogliptin NS TECOS 2015 Sitagliptin NS ELIXA 2015 Lixisenatide NS EMPA-REG 2015 Empagliflozin *CV mortality, non-fatalmi, non-fatalstroke ,2 Favors placebo Favors study drug
12 Potential of SGLT2 Inhibition Filtered glucose load > 180 g/die 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% SGLT2 SGLT1 SGLT2 inhibitors reduce glucose reabsorption at the proximal tubule causing glycosuria and osmotic diuresis
13 EMPA-REG CV OUTCOME Main Results Patients with event/analysed Empagliflozin Placebo HR (95% CI) p-value 3-point MACE 490/ / (0.74, 0.99)* CV death 172/ / (0.49, 0.77) < Non-fatal MI 213/ / (0.70, 1.09) Non-fatal stroke 150/ / (0.92, 1.67) Favours empagliflozin Favours placebo Zinman B et al N Engl J Med 2015;373:
14 EMPA-REG Outcomes Incident or Worsening Nephropathy Wanner C et al N Engl J Med 2016;375:323-34
15 CANVAS - Primary MACE Outcome: CV Death, Nonfatal Myocardial Infarction or Nonfatal Stroke Neal B et al N Engl J Med 2017 Neal B, et al. N Engl J Med. 2017
16 Key Outcomes in the CANVAS Program and EMPA-REG OUTCOME Zinman Bet al. N Engl J Med. 2015;373: ; Wanner K et al. N Engl J Med. 2016;375: ; Neal B et al N Engl J Med DOI: /NEJMoa
17 SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials 1/3 in primary prevention in Canvas Subjects with prior CV events in the CANVAS trial had 18% reduction in CV death (HR 0.82, 95% CI ) compared to only 2% in those without prior CV events (HR 0.98, 95% CI ). 40% of deaths in the EMPA-REG trial were due to undefined causes, which were assessed as CV deaths. After elimination of these nonassessable deaths from the analysis, the superiority of empagliflozin was abrogated (HR 0.90, 95% CI )
18 The CVD-REAL (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors) study was a multinational, observational study in which adults with type 2 diabetes were identified. Patients newly prescribed an SGLT-2i or other glucose-lowering drugs (GLDs) were matched based on a propensity score 153,078 patients were included in each group (total 306,156). At baseline, 13% had established CVD. In the SGLT-2i group, 53.2% of patients received canagliflozin, 41.4% received dapagliflozin, and 5.4% empagliflozin.
19 Kosiborod M. et al.: al Journal of the American College of Cardiology (2018) CVD-REAL Data Sources: Health Records Across Six Countries
20 Event Rates in Patients With and Without Cardiovascular Disease Stratified by Treatment With SGLT2 Inhibitors or Other Glucose- Lowering Drugs
21 Cavender, M.A. et al. J Am Coll Cardiol. 2018;71(22): Outcomes in patients with and without cardiovascular disease at baseline
22 Lower Cardiovascular Risk Associated with SGLT-2 inhibitors Kosiborod M. et al.: al Journal of the American College of Cardiology (2018) P-value for SGLT2i vs ogld: <.001
23 Conclusions - CVD Real In > patients with Type 2 diabetes, treatment with SGLT-2 inhibitors versus other oglds was associated with significant reductions in: All-cause death Hospitalization for heart failure Myocardial infarction and stroke Broad population of patients with Type 2 diabetes in general practice, the overwhelming majority (87%) did not have known cardiovascular disease Benefits may extend to those at the lower end of the risk spectrum HHF and death analyses similar to those seen in EMPA-REG OUTCOME The cardiovascular benefits of SGLT-2i may not be specific to a single compound, and may extend to a broader population of patients with T2D than previously considered Kosiborod M. et al.: al Journal of the American College of Cardiology (2018)
24 primary composite outcome (HR, 0.57; 95% CI, ; P < EASEL Circulation 2018
25 Possible Mechanisms Accounting for EMPA-REG OUTCOME Results Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA et al Diabetes Care 2016;39:
26 Glycated Hemoglobin Levels -0.3% EMPA-Reg NEJM 2015
27 POTENTIAL MECHANISMS TO EXPLAIN CV BENEFIT Glucose Control Hyperglycemia is a weak risk factor for CV disease. Intensive glycemic control failed to decrease CV events in ACCORD, ADVANCE and VADT studies in T2D patients with longstanding diabetes duration. HbA1c reductions of >1% in ACCORD and ADVANCE had no benefit on MACE In UKPDS and VADT it took 10 years to demonstrate a small (- 10%), significant, reduction in CV events
28 Possible Mechanisms Accounting for EMPA-REG OUTCOME Results Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA et al Diabetes Care 2016;39:
29 EMPA-REG CV OUTCOME Effects on Systolic BP Placebo Empagliflozin 25 mg Empagliflozin 10 mg Placebo 2322 Empagliflozin 10 mg 2322 Empagliflozin 25 mg
30 CANVAS Program - Effects on Systolic BP
31 Baker WL et al J Am Soc Hypertens 2014;8: Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Blood Pressure Diastolic Blood Pressure Systolic Blood Pressure
32 Relationship between Changes in BP and Urinary Na + and Glucose Excretion after 2-week SGLT2 inhibitors Kawasoe et al. BMC Pharmacol Toxicol 2017;18:23-33
33 Relationship between Changes in BP and Urinary Na + and Glucose Excretion after 6-month SGLT2 inhibitors Kawasoe et al. BMC Pharmacol Toxicol 2017;18:23-33
34 Possible Mechanisms Accounting for EMPA-REG OUTCOME Results Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA et al Diabetes Care 2016;39:
35 Conclusions SGLT2 inhibitors In patients with Type 2 diabetes, treatment with SGLT-2 inhibitors is associated with significant reductions in: All-cause death Hospitalization for heart failure Myocardial infarction and stroke Mechanisms may involve, sodium excretion, lowering of blood pressure,. Efficacy in secondary prevention, but possibly also in primary prevention The cardiovascular benefits of SGLT-2i may not be specific to a single compound, and may extend to a broader population of patients with T2D than previously considered
36 Effect of Glucose-Lowering Drugs on 3-Point MACE* in T2DM Patients Study Year Glucose-lowering drug HR 95% CI P-value PROACTIVE 2005 Pioglitazone ORIGIN 2012 Insulin glargine NS DEVOTE 2017 Insulin degludec NS SAVOR 2013 Saxagliptin NS EXAMINE 2013 Alogliptin NS TECOS 2015 Sitagliptin NS ELIXA 2015 Lixisenatide NS EMPA-REG 2015 Empagliflozin LEADER 2016 Liraglutide SUSTAIN Semaglutide CANVAS 2017 Canagliflozin ,2 *CV mortality, non-fatal MI, non-fatal stroke Favors study drug Favors placebo
37 GLP-1 targets multiple organs to improve glucose control in T2DM
38 Anti-Atherosclerotic potential of GLP-1 action
39 GLP-1R Dependent Intracellular Signal Pathways in the Cardiomyocyte
40
41 Effect of GLP-1 RAs on CVD outcome Bethel MA et al Lancet 2018
42 Effect of GLP-1 RAs on CVD outcome Bethel MA et al Lancet 2018
43 LEADER & SUSTAIN 6 Renal Outcomes LEADER - Time to first renal event SUSTAIN-6 - New or Worsening Nephropathy Placebo HR, % CI ( ) p=0.005 Semaglutide Marso SP et al N Engl J Med. 2016;375:311-22; Marso SP et al N Engl J Med. 2016;375:
44 SUSTAIN-6 - Systolic Blood Pressure Overall mean at baseline: mmhg ETD: 2.59* [ 4.09; 1.08] ETD: 1.27 [ 2.77;0.23] Marso SP et al N Engl J Med. 2016;375:
45 Meta-analysis of Change in Systolic (top) and Diastolic Blood Pressure (mmhg) in T2DM Patients Treated with GLP1-Ra Visboll T et al BMJ 2012;344:d7771 doi: /bmj.d7771
46 Effect of 3h GLP-1 infusion on Urine Fluid and Electrolyte Output in Healthy Subjects P= P= P= P= Gutzwiller J-P et al J Clin Endocrinol Metab 2004;89:
47 Possible Mechanisms Regulating Antihypertensive Effect(s) of Incretin-based Diabetes Therapies Lovshin JA, Zinman B Can J Diabetes 38;2014:364e371
48 Glycated Hemoglobin and Body Weight in SUSTAIN 6 Marso SP et al. N Engl J Med 2016.
49 Selective Targeting of GLP-1 Signalling as a Novel Therapeutic Approach for CVD in Diabetes Tate M et al British Journal of Pharmacology 2015;
50 GLP-1 RA e CVD: open questions.. Only the LEADER trial of liraglutide and the SUSTAIN 6 trial of semaglutide met their prespecified criteria for statistical significance. The results of the ELIXA trial of lixisenatide did not show any trend toward cardioprotection, EXSCEL trial of extended-release exenatide represented an apparent near miss with respect to statistical significance Differences in the study design might have contributed to the absence of cardioprotection with lixisenatide. ELIXA was done in the setting of acute coronary syndrome, LEADER, SUSTAIN 6, and EXSCEL were done in chronic settings in relatively stable patients Differences in HbA1c reduction between compunds
51 Magnitude of cardioprotection and HbA1c lowering with GLP-1 receptor agonists Taylor SI. GLP-1 receptor agonists: differentiation within the class. Lancet 2018
52 OBJECTIVE To compare the efficacies of SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors on mortality and cardiovascular end points using network meta-analysis 236 trials randomizing participants The primary outcome: all-cause mortality; secondary outcomes: cardiovascular (CV) mortality, heart failure (HF) events,myocardial infarction (MI), unstable angina, and stroke
53 Network Plot for All Studies Zheng SL et al. JAMA April 17, 2018
54 Forest Plots for All-Cause Mortality Zheng SL et al. JAMA April 17, 2018
55 Ranking Plos for All-Cause Mortality Zheng SL et al. JAMA April 17, 2018
56 In conclusione. in prevenzione secondaria SGLT2 inhibitors e GLP-1 analoghi si sono dimostrati efficaci nel ridurre gli eventi CV e la mortalità, e devono essere presi in considerazione nella terapia del diabete. I meccanismi coinvolti sembrano essere sia glicemici che extra-glicemici I risultati dei trials sono quasi tutti in in prevenzione secondaria, ma quelli di real-world sono derivati da pazienti in prevenzione primaria. Risultati estrapolabili su tutti?
57
La lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationIl Dr. Giampaolo Niccoli dichiara di non aver ricevuto negli ultimi due anni compensi o finanziamenti da Aziende Farmaceutiche e/o Diagnostiche:
Il Dr. Giampaolo Niccoli dichiara di non aver ricevuto negli ultimi due anni compensi o finanziamenti da Aziende Farmaceutiche e/o Diagnostiche: Dichiara altresì il proprio impegno ad astenersi, nell ambito
More information- Johnson & Johnson - Roche S.p.a. - Healthware per Sanofi
Il dr. Pintaudi Basilio dichiara di aver ricevuto negli ultimi due anni compensi o finanziamenti dalle seguenti Aziende Farmaceutiche e/o Diagnostiche: - Johnson & Johnson - Roche S.p.a. - Healthware per
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationGli endpoint micro-vascolari nei trial di outcome cardiovascolare
Gli endpoint micro-vascolari nei trial di outcome cardiovascolare Giorgio Sesti University Magna Graecia of Catanzaro ITALY Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di aver ricevuto
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationEmanuele Bosi dichiara di aver ricevuto negli ultimi due anni compensi o finanziamenti dalle seguenti Aziende Farmaceutiche e/o Diagnostiche:
Emanuele Bosi dichiara di aver ricevuto negli ultimi due anni compensi o finanziamenti dalle seguenti Aziende Farmaceutiche e/o Diagnostiche: - Abbott - Roche - Takeda - Novartis - Astra Zeneca - Medtronic
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More informationIl razionale delle associazioni terapeutiche sulla protezione cardiovascolare
Il razionale delle associazioni terapeutiche sulla protezione cardiovascolare Alessandra Dei Cas UOC di Endocrinologia e Malattie del Metabolismo Dipartimento di Medicina e Chirurgia Università di Parma
More informationNew Strategies for Cardiovascular Risk reduction in Diabetes
New Strategies for Cardiovascular Risk reduction in Diabetes Dr. Godwin LEUNG Tat Chi MB ChB(HK), MRCP (UK), FHKCP, FHKAM (Medicine) FRCP (Glasg), FACC Specialist in Cardiology % event as first CV event
More informationCardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician
Biomarkers 2019 Cardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationLa protezione cardiovascolare degli inibitori di SGLT2: trial e studi osservazionali
La protezione cardiovascolare degli inibitori di SGLT2: trial e studi osservazionali Saula Vigili de Kreutzenberg Studi di Padova Università degli Il /la dr./sa Saula Vigili de Kreutzenberg dichiara di
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationEffect of SGLT-2 Inhibitors on the Heart. Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic
Effect of SGLT-2 Inhibitors on the Heart Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic Disclosures Speaker - Johnson and Johnson - Merck Research - Merck - Novo
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationEndocrinologist Sweetgrass Endocrinology
Endocrinologist Sweetgrass Endocrinology Sanders, Cummings Ask Justice Department to Investigate Insulin Prices The Department of Justice and the FTC are asked to investigate whether Lilly, Novo Nordisk,
More informationCosa aggiungono gli inibitori di SGLT2 in termini di nefro-protezione?
Cosa aggiungono gli inibitori di SGLT2 in termini di nefro-protezione? Giuseppe Pugliese Dipartimento di Medicina Clinica e Molecolare Università di Roma "La Sapienza Disclosure Il Prof. Giuseppe Pugliese
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationCardiovascular Impact of Medications for Treating Type 2 Diabetes
Friday CME Breakfast Lecture Cardiovascular Impact of Medications for Treating Type 2 Diabetes Thomas Blevins, MD Endocrinologist, Private Practice Texas Diabetes and Endocrinology Austin, Texas Educational
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationIn compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants:
In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: Entity Activity Financial Consideration Comments Novo Nordisk
More informationImpatto dei farmaci antidiabetici sullo scompenso cardiaco
Impatto dei farmaci antidiabetici sullo scompenso cardiaco Riccardo Candido S.S.D. Gestione Rete Diabetologica Aziendale Azienda Sanitaria Universitaria Integrata di Triste Il sottoscritto Riccardo Candido
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationMulti-factor approach to reduce cardiovascular risk in diabetes
Multi-factor approach to reduce cardiovascular risk in diabetes Prof. Nicola Napoli, MD PhD Division of Endocrinology and Diabetes Università Campus Bio-Medico di Roma Washington University in St Louis
More informationNewer Therapies for Type 2 Diabetes
Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationDiabetes Management in CAD Patients. Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts
Diabetes Management in CAD Patients Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts Disclosure Stuart R. Chipkin, MD, FACE Nothing to disclose
More informationFarmaci innovativi e terapie di associazione: quali opportunità? Giuseppe Penno Dipartimento di Medicina Clinica e Sperimentale
Farmaci innovativi e terapie di associazione: quali opportunità? Giuseppe Penno Dipartimento di Medicina Clinica e Sperimentale Dichiarazione esplicita di trasparenza delle fonti di finanziamento e dei
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationrazionale della combinazione insulina/glp-1 RAs
Insulina e GLP-1 RAS: insieme o separati? razionale della combinazione insulina/glp-1 RAs Catania Mercure Catania Excelsior 10 ottobre 2017 Andrea Giaccari andrea.giaccari@unicatt.it Centro per le Malattie
More informationGlucose Lowering Medications and CV Risk Reduction: A New Era Jane EB Reusch MD ADA President for Medicine and Science
Glucose Lowering Medications and CV Risk Reduction: A New Era Jane EB Reusch MD ADA President for Medicine and Science Professor of Medicine, Division of Endocrinology, Metabolism and Diabetes and Associate
More informationHEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD
HEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD Author affiliations: Department of Cardiology, Hôpital Saint Joseph, Paris, France Address for correspondence: Michel Komajda,
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationGabriele Perriello Dipartimento di Medicina Interna Azienda Ospedaliera-Universitaria di Perugia. Metformina, sulfoniluree, pioglitazone
Gabriele Perriello Dipartimento di Medicina Interna Azienda Ospedaliera-Universitaria di Perugia Metformina, sulfoniluree, pioglitazone Hypoglycemic therapy and CV risk Combination of SUs and Metformin
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationReview of FDA Guidance on Cardiovascular Outcomes for Diabetes Medication Trials and Application to Clinical Management
Katherine S. O Neal Pharm.D., MBA, BCACP, CDE, BC-ADM, AE-C Associate Professor The University of Oklahoma Health Sciences Center College of Pharmacy Department of Internal Medicine Oklahoma City, OK Member,
More informationThe Role Of SGLT-2 Inhibitors In Clinical Practice. Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs
The Role Of SGLT-2 Inhibitors In Clinical Practice Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs Disclosure of Potential Conflicts of Interest Consultantship
More informationPROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationCurrent Updates & Challenges In Managing Diabetes in CVD
Current Updates & Challenges In Managing Diabetes in CVD Preventive Cardiovascular Conference 2016 Instituit Jantung Negara 12 th November 2016 Nor Azmi Kamaruddin Diabetes Clinic Department of Medicine
More informationDisclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017
Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials Shannon Wakeley MD Complete Endocrinology 9/2/2017 Disclosures Speakers Bureau: Astra Zeneca, Sanofi, Abbvie, Boehringer-Ingelheim, Medtronic,
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationUpdate Diabetes Therapie. Marc Y Donath
Update Diabetes Therapie Marc Y Donath Recent CV outcome studies in Diabetes N Engl J Med. 2015 373:2117-28 (Empa-Reg outcome study) N Engl J Med. 2016 June 13 (LEADER trial) N Engl J Med. 2017 June 12
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationDiabetes Drugs and Cardiac Disease. Disclosures
Diabetes Drugs and Cardiac Disease Robert J. Rushakoff, MD Professor of Medicine University of California, San Francisco robert.rushakoff@ucsf.edu Disclosures None 1 Written Comments As I have said every
More informationEducational Objectives
Educational Objectives Recognize the rationale for cardiovascular outcome trials (CVOTs) in T2DM and review data from recent CVOTs of anti hyperglycemic agents Examine alignment of managed care T2DM treatment
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationSodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes
Editorial Page 1 of 5 Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes Hidekatsu Yanai Department of Internal Medicine, National Center for Global Health and Medicine
More informationDISCLOSURES. Learning objectives NAVIGATING THE TREATMENT OF TYPE 2 DIABETES: WHAT S NEW? Investigator Initiated Trial Support:
NAVIGATING THE TREATMENT OF TYPE 2 DIABETES: WHAT S NEW? Jane E-B Reusch MD Professor of Medicine, Biochemistry and Bioengineering Associate Director Center for Women s Health Research University of Colorado
More informationNewer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThe Alphabet Soup of Diabetes. Egils Bogdanovics M.D. Hungerford Diabetes Center
The Alphabet Soup of Diabetes Egils Bogdanovics M.D. Hungerford Diabetes Center Insulin: January 11, 1922 12 year old Leonard Thompson, on a starvation diet for 2 years received his first insulin injection
More informationMaking Sense of New DM Therapies and Technologies
Making Sense of New DM Therapies and Technologies Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and
More informationCardiovascular Consequences of Diabetes Mellitus
Cardiovascular Consequences of Diabetes Mellitus William J. Elliott, M.D., Ph.D. 05 MAY 18 Disclosure Statement The speaker s research and educational activities have been supported in the past (but NOT
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationType 2 diabetes and cardiovascular risk: the role of GLP-1
Type 2 diabetes and cardiovascular risk: the role of GLP-1 Dr Isidora Kitsou-Mylona, PhD Novo Nordisk Regional Medical Advisor Business Area Africa, Gulf & India Disclaimer I am an employee of Novo Nordisk
More informationOral Agents in Type 2 DM
Oral Agents in Type 2 DM CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationStephen Clement M.D. CDE Medical Director, Endocrine Services Inova Fairfax Hospital
Stephen Clement M.D. CDE Medical Director, Endocrine Services Inova Fairfax Hospital Financial Disclosures Consulting Panel for GSK on Hepatitis Vaccines Case Study BH is a 67 y/o female with T2 DM for
More informationDrug Class Update with New Drug Evaluation: Non-insulin Diabetes Treatments (SGLT-2 Inhibitors and GLP-1 Receptor Agonists)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNuove opportunità terapeutiche nel Diabete Mellito
Nuove opportunità terapeutiche nel Diabete Mellito Raffaele Napoli UOSD Medicina Interna ad indirizzo Diabetologico Dipartimento di Scienze Mediche Traslazionali, Università Federico II di Napoli 1 Potenziali
More informationSGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More informationSGLT2 and cardiovascular events: Why did EMPA-REG Outcomes surprise and what were the likely mechanisms? David Preiss, 3 John J McMurray 1
SGLT2 and cardiovascular events: Why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Naveed Sattar, 1 James McLaren, 1 Søren L Kristensen, 2 David Preiss, 3 John J McMurray 1 1 Institute
More informationQuando l insulina basale non basta più: differenti e nuove strategie terapeutiche
Quando l insulina basale non basta più: differenti e nuove strategie terapeutiche Giorgio Sesti Università Magna Graecia di Catanzaro Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di
More informationEmergence of the New Classes of Compounds for Managing Heart Disease in Diabetes Mellitus
Emergence of the New Classes of Compounds for Managing Heart Disease in Diabetes Mellitus Mikhail Kosiborod, MD Professor of Medicine (Cardiology) Saint Luke s Mid America Heart Institute University of
More informationNew Therapies for Type 2 Diabetes
New for Type 2 Diabetes Joshua J. Joseph, MD Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio State University Wexner Medical Center Financial Disclosures: None
More informationCONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE. AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY. sul Paziente ad alto rischio CV*
CONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY sul Paziente ad alto rischio CV* Does reducing hyperglycemia protect against cardiovascular risk?
More informationNew Therapies for Type 2 Diabetes
New for Type 2 Diabetes Joshua J. Joseph, MD Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio State University Wexner Medical Center Financial Disclosures: None
More informationTYP 2 DIABETES. Marc Donath
TYP 2 DIABETES Marc Donath Treatment of Typ 2 Diabetes GLP-1 Anti-IL-1β Insulin sulfonylureas Metformin UCP-1 IL-1β Sport SGLT2i Bariatric surgery Cardiomyocytes Control Glucose Dyntar et al. Diabetes
More informationContent Development Committee
1 Content Development Committee Cardiologists: Family Physicians: Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA, FCCS (Chair) Associate Head, Division of Cardiology, St. Michael s Hospital Professor,
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More information2019 Update on Recent Guideline Releases for Diabetes, Hypertension, and Dyslipidemia: Can We, Please, All Just Get on the Same Page?!
2019 Update on Recent Guideline Releases for Diabetes, Hypertension, and Dyslipidemia: Can We, Please, All Just Get on the Same Page?! Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM Assistant Professor,
More informationFaculty. Robert S. Busch, MD, FACE Director of Clinical Research Albany Medical Faculty: Community Endocrine Group Albany, NY
Faculty Robert S. Busch, MD, FACE Director of Clinical Research Albany Medical Faculty: Community Endocrine Group Albany, NY 2 Disclosures Robert S. Busch, MD, FACE serves as a speaker for Astra Zeneca,
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationMANAGING THE HYPERGLYCEMIA OF DIABETES: SHOULD CVOTs IMPACT MEDICATIONS?
MANAGING THE HYPERGLYCEMIA OF DIABETES: SHOULD CVOTs IMPACT MEDICATIONS? Ralph A. DeFronzo, M.D. Professor of Medicine Chief, Diabetes Division University of Texas Health Science Center San Antonio, Texas
More informationTHE EVOLUTION OF CLINICAL TRIALS IN T2DM: FROM TARGETING A1C TO TARGETING CARDIOVASCULAR OUTCOMES
Learning Objectives 1) Evaluate the interrelationship between diabetes, glycemic control, and cardiovascular disease. 2) Examine the evolution of type 2 diabetes (T2DM) drug development and factors leading
More informationNew Approaches for Treating Challenging Patients with Diabetes
New Approaches for Treating Challenging Patients with Diabetes Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs Disclosure of Potential Conflicts of Interest
More information